Core Viewpoint - Silo Pharma, Inc. has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent related to pharmacological prophylactics against stress-induced affective disorders in females, which will enhance the protection of its lead asset, SPC-15, an intranasal treatment for PTSD [1][2]. Company Overview - Silo Pharma is a developmental stage biopharmaceutical company focused on creating novel therapeutics for underserved conditions, including stress-induced psychiatric disorders and chronic pain [4]. - The company is developing both traditional therapies and psychedelic treatments, with its lead program being SPC-15, aimed at treating PTSD and stress-induced anxiety disorders [4]. Patent and Intellectual Property - The newly allowed patent broadens the protection for SPC-15 and expands the company's technology rights, reinforcing its intellectual property portfolio [2]. - Silo holds an exclusive license agreement with Columbia University for the development, manufacturing, and commercialization of SPC-15 globally, which includes extensive issued patents and pending applications [2]. Product Details - SPC-15 is a serotonin 5-HT4 receptor agonist designed to treat stress-induced disorders such as PTSD and anxiety, delivered via an intranasal formulation [3]. - The product may qualify for the FDA’s streamlined 505(b)(2) regulatory pathway, potentially accelerating its approval process [3]. - Silo is currently collaborating with Columbia University on preclinical studies for SPC-15 [3].
Silo Pharma Awarded US Patent for Groundbreaking PTSD Treatment and Prepares for SPC-15 Clinical Trial